The Role of Theranostics and Vaccines in Early Diagnosis and Therapeutic Strategies in Different Diseases 16.3 Vaccine 16.4 Conclusions References
22 17 Toxicological Concerns of Nanomaterials Used in Biomedical Applications 17.1 Introduction 17.2 Factors Influencing the Toxicity of Nanoparticles 17.3 Why Is Toxicity Evaluation of Nanomaterials Necessary? 17.4 Toxicity of Nanomaterials Used in Biomedical Applications 17.5 Surface Engineering to Avoid Nanotoxicity 17.6 Conclusion and Future Perspectives Acknowledgments References
23 Index
List of Tables
1 Chapter 4Table 4.1 Examples of commercially available Gd3+ chelate T1‐Weighted MRI con...Table 4.2 Examples of commercially available IONP‐based T2‐weighted MRI contr...Table 4.3 Typical combined applications of Au NRs.
2 Chapter 7Table 7.1 Superparamagnetic iron oxide nanoparticle‐based AMF‐induced in vitr...Table 7.2 Superparamagnetic iron oxide nanoparticle‐based AMF‐induced in vivo...
3 Chapter 8Table 8.1 Various plant virus nanoparticles and their potential applications ...
4 Chapter 9Table 9.1 Classification of iron oxide particles according to their size.
5 Chapter 10Table 10.1 Factors affecting antimicrobial activity of chitosan.
6 Chapter 11Table 11.1 Various biomaterials used for synthesis of SNPs.
7 Chapter 12Table 12.1 Details about antifungal efficacy of different nanoparticles again...
8 Chapter 13Table 13.1 Examples of commercially available antifungal nanoformulated drugs...
9 Chapter 14Table 14.1 Dose‐dependent RBC lysis assay of ChBio‐AgNPs.
10 Chapter 15Table 15.1 Clinical and epidemiological characteristics of the mainLeishmaniaTable 15.2 Chemical structure and selected properties of existing antileishma...Table 15.3 A survey of reports on polymeric nanoparticles made from biodegrad...Table 15.4 Micellar drug delivery devices made from copolymers as appearing i...Table 15.5 Nanodrug delivery devices intended for treatment of leishmanial in...Table 15.6 Some selected reports on using bioconjugate drug delivery devices ...Table 15.7 Some selected reports on using inclusion compounds for treatment o...Table 15.8 Drug delivery devices developed for antileishmanial agents based o...Table 15.9 Selected liposomal drug delivery systems appearing in the literatu...Table 15.10 Other vesicular nanoparticles including niosomes, emulsomes, and ...Table 15.11 Nanodrug delivery vehicles based on solid lipid nanoparticles and...Table 15.12 Micro‐ and nanoemulsion products reported for treatment of leishm...Table 15.13 Nanodrug and nanosuspension products reported for treatment of le...Table 15.14 Inorganic nanoparticles used as antileishmanial agents per se or ...
11 Chapter 16Table 16.1 Vaccine‐theranostics that potentiate active antigens into cells to...Table 16.2 Evaluation of nanotherapy by imaging in cardiovascular illness as ...
List of Illustrations
1 Chapter 1Figure 1.1 Schematic illustration of various inorganic nanomaterials.Figure 1.2 Schematic representation of various organic nanomaterials.Figure 1.3 Role of nanotechnology and nanomaterials in diagnostics and its a...Figure 1.4 Schematic representation of the operating principle of the biosen...Figure 1.5 A general scheme of similar colorimetric nanosensors.Figure 1.6 Schematic representation of comparison between untargeted and tar...
2 Chapter 2Figure 2.1 Nanocomposite of elemental selenium and arabinogalactan, fluoresc...Figure 2.2 The emission spectra of the nanocomposite elemental selenium and ...Figure 2.3 The nuclei of Ehrlich's carcinoma cells after exposure to nanocom...Figure 2.4 Ehrlich's carcinoma cells after exposure to nanocomposite element...Figure 2.5 Regenerative process during fracture (a) The control group. Bone ...Figure 2.6 The effect of the nanocomposite of elemental selenium and arabino...
3 Chapter 3Figure 3.1 Nanoliposome as a carrier for drug delivery.Figure 3.2 Chitosan nanoparticles loaded with drugs.Figure 3.3 Mechanism of Helicobacter pylori inactivation in epithelium cells...
4 Chapter 4Figure 4.1 (a) Photograph and thermal image of a mouse exposed to ACMF for 2...Figure 4.2 Gold‐based nanotheranostic agents. (a) Schematic illustration of ...Figure 4.3 Nanotheranostics against Alzheimer's. (a) Fluorescence imaging of...Figure 4.4 QD‐Apt(Dox) Bi‐FRET system as novel theranostic agent against can...Figure 4.5 Schemes for the generation of reactive oxygen species, EPR effect...Figure 4.6 Polymeric nanoparticles against teratocarcinoma: (a) Dendritic co...Figure 4.7 In vivo photothermal therapeutic evaluation using silica‐based th...Figure 4.8 Synthesis and application of UCMSNs in imaging. (a) Schematic ill...Figure 4.9 Characterization of LPSiNPs and their applications in imaging. (a...Figure 4.10 TEM images of SPIO@Lac‐Gly (a, b) and CNT‐PDDA‐SPIO@Lac‐Gly (c, ...Figure 4.11 Graphene‐encapsulated particles in biomedical applications (ii)....
5 Chapter 5Figure 5.1 Schematic description of Epi‐loaded‐NAS‐24‐functionalized PEI‐PEG...Figure 5.2 Schematic representation of the MUC1 aptamer‐modified PLGA‐Epi‐Pβ...Figure 5.3 Schematic illustration of the polyvalent aptamer‐based structure ...Figure